SCHEMBL2374726

SCHEMBL2374726

OCCOc1ncc(C=Cc2ccc(O)cc2)cc1Br

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 15/20 1.00
TRPA1 O75762 2/20 0.49
NPC1 O15118 2/20 0.46
MTOR P42345 2/20 0.46
KMT2A Q03164 3/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA3 P07451 2/20 0.42
CA4 P22748 2/20 0.42
CA6 P23280 2/20 0.42
CA5A P35218 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA13 Q8N1Q1 2/20 0.42
CA14 Q9ULX7 2/20 0.42
CA5B Q9Y2D0 2/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374723 1.00 APP (1.00) APPTRPA1NPC1MTORKMT2A
SCHEMBL2386942 0.85 APP (1.00) APPTRPA1NPC1MTORMAPT
SCHEMBL2386947 0.85 APP (1.00) APPTRPA1NPC1MTORMAPT
SCHEMBL2373704 0.84 APP (1.00) APPNPC1KMT2AMEN1MAPT
SCHEMBL2373698 0.84 APP (1.00) APPNPC1KMT2AMEN1MAPT
SCHEMBL2374135 0.84 APP (1.00) APPMAPT
SCHEMBL2374125 0.84 APP (1.00) APPMAPT
SCHEMBL2373289 0.81 APP (0.67) APPNPC1KMT2AKDM4EMEN1
SCHEMBL2373283 0.81 APP (0.67) APPNPC1KMT2AKDM4EMEN1
SCHEMBL14026013 0.79 APP (0.66) APPTRPA1NPC1MTORKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363392-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2017-05-03 EP disclosed
EP-1999109-B1 STYRYLPYRIDINE DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLAQUES UNIV PENNSYLVANIA (US) 2011-12-28 EP disclosed
EP-2363391-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
EP-2363392-A1 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques The Trustees of The University of Pennsylvania (US) 2011-09-07 EP disclosed
US-7687052-B2 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2010-03-30 US disclosed
US-20080038195-A1 radiolabeling; neurodegenerative diseases THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038195-A1 radiolabeling; neurodegenerative diseases APP, PSEN1, HTT APP 1/4885TRPA1 3911/4885NPC1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.